In December 2017, we entered into a licensing agreement with MEDINET Co., Ltd., a pioneering leader in the development and commercialization of cancer immuno-cell therapy technologies for the development and commercialization of NeoCart for the Japanese market.
Under the license agreement, MEDINET will be responsible for development and commercialization in Japan, including a 30-patient clinical study in Japanese patients. Histogenics will manufacture NeoCart for a Phase 3 clinical trial in Japan and potential commercial quantities.
View more about MEDINET on their website.
If you are interesting in partnering opportunities with Histogenics, please email us at InvestorRelations@histogenics.com